Figure 1

Tumour blood flow changes caused by AC7700 in tumours growing in various tissues and organs. AC7700 at 10 mg kg⁻¹ or 0.9% NaCl solution was infused via the lateral tail vein at the rate of 0.15 ml min⁻¹ by an infusion pump at 0 min. The TBF significantly decreased in all tumours after AC7700 administration compared with the control group. The TBF of tumours in the liver, muscle, and lymph node was completely stopped 30–60 min after AC7700 administration. (A) tumour growing in the liver (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg⁻¹ AC7700 (n=10), P=0.0007); (B) tumour growing in the muscularis propria of the stomach (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg⁻¹ AC7700 (n=14), P=0.0118); (C) tumour growing in the kidney (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg⁻¹ AC7700 (n=10), P=0.0004); (D) tumour growing in the muscle (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg⁻¹ AC7700 (n=10), P=0.0243); (E) metastatic foci in the cervical lymph node (open circle, 0.9% NaCl solution (n=8) vs solid circle, 10 mg kg⁻¹ AC7700 (n=10), P=0.0065).